NABI BIOPHARMACEUTICALS ANNOUNCES RESULTS FROM BACTERIA VACCINE TRIALS
Nabi Biopharmaceuticals has provided an update on the development of its gram-positive
infections program, which includes several product candidates for the prevention
and treatment of S. aureus, S. epidermidis and enterococcal infections. Together
these bacteria account for two-thirds of healthcare-associated infections
Nabi reported positive data from Phase I studies of the company's S. epidermidis PS-1 vaccine and its S. aureus Type 336 vaccine. Both Phase I studies evaluated the safety and immune response of these vaccines in healthy volunteers. The data support that escalating doses of the vaccines were well tolerated and resulted in significant dose-related increases in levels of antibodies against S. epidermidis PS-1 and S. aureus Type 336. The results of these studies also support the company's conjugation technology in stimulating antibody responses.